AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive su...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00235/full |
| _version_ | 1817999450529857536 |
|---|---|
| author | Georgiopoulos Georgios Vasiliki Katsi Dimitrios Oikonomou Georgia Vamvakou Evangelia Koutli Aggeliki Laina Constantinos Tsioufis Petros Nihoyannopoulos Petros Nihoyannopoulos Dimitrios Tousoulis |
| author_facet | Georgiopoulos Georgios Vasiliki Katsi Dimitrios Oikonomou Georgia Vamvakou Evangelia Koutli Aggeliki Laina Constantinos Tsioufis Petros Nihoyannopoulos Petros Nihoyannopoulos Dimitrios Tousoulis |
| author_sort | Georgiopoulos Georgios |
| collection | DOAJ |
| description | Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). Methods: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety and possible clinical role of AZL-M in hypertensive diabetic patients.Results: AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. Conclusion: Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research. |
| first_indexed | 2024-04-14T03:09:09Z |
| format | Article |
| id | doaj.art-30a99f0e2d7543bd882000c324b09bfd |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-14T03:09:09Z |
| publishDate | 2016-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-30a99f0e2d7543bd882000c324b09bfd2022-12-22T02:15:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-08-01710.3389/fphar.2016.00235210788AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.Georgiopoulos Georgios0Vasiliki Katsi1Dimitrios Oikonomou2Georgia Vamvakou3Evangelia Koutli4Aggeliki Laina5Constantinos Tsioufis6Petros Nihoyannopoulos7Petros Nihoyannopoulos8Dimitrios Tousoulis91st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Internal Medicine, 'Hippokration' Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of Athens1st Department of Cardiology, ‘Hippokration’ Hospital, University of AthensDepartment of Cardiology, Imperial College London, Hammersmith Hospital1st Department of Cardiology, ‘Hippokration’ Hospital, University of AthensBackground: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). Methods: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety and possible clinical role of AZL-M in hypertensive diabetic patients.Results: AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. Conclusion: Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00235/fullDiabetes MellitusHypertensioncardiovascularmetabolicAzilsartan medoxomilPleiotropic |
| spellingShingle | Georgiopoulos Georgios Vasiliki Katsi Dimitrios Oikonomou Georgia Vamvakou Evangelia Koutli Aggeliki Laina Constantinos Tsioufis Petros Nihoyannopoulos Petros Nihoyannopoulos Dimitrios Tousoulis AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. Frontiers in Pharmacology Diabetes Mellitus Hypertension cardiovascular metabolic Azilsartan medoxomil Pleiotropic |
| title | AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. |
| title_full | AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. |
| title_fullStr | AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. |
| title_full_unstemmed | AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. |
| title_short | AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY. |
| title_sort | azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects a review study |
| topic | Diabetes Mellitus Hypertension cardiovascular metabolic Azilsartan medoxomil Pleiotropic |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00235/full |
| work_keys_str_mv | AT georgiopoulosgeorgios azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT vasilikikatsi azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT dimitriosoikonomou azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT georgiavamvakou azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT evangeliakoutli azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT aggelikilaina azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT constantinostsioufis azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT petrosnihoyannopoulos azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT petrosnihoyannopoulos azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy AT dimitriostousoulis azilsartanasapotentantihypertensivedrugwithpossiblepleiotropiccardiometaboliceffectsareviewstudy |